Press releases

27
Sep 2023
20:30 E.S.T.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more
7
Aug 2023
13:41 E.S.T.

Cellectis Provides Full Report for Second Quarter 2023 Financial Results

Read more
3
Aug 2023
16:52 E.S.T.

Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023

Read more
26
Jul 2023
13:47 E.S.T.

Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023

Read more
12
Jul 2023
14:29 E.S.T.

Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors

Read more
28
Jun 2023
14:33 E.S.T.

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 27, 2023

Read more
8
Jun 2023
14:38 E.S.T.

Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023

Read more
5
Jun 2023
16:26 E.S.T.

Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event

Read more
31
May 2023
20:18 E.S.T.

Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies

Read more
24
May 2023
23:05 E.S.T.

Cellectis’ Annual Shareholders General Meeting to be Held on June 27, 2023

Read more

Press contacts

For more information on any story, or for press enquiries, get in touch with our communication team

CONTACT US